Matija Snuderl
Small-cap, biotech, healthcare, growth

Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin

I have long planned to write my opinion on Cellceutix (OTCPK:CTIX), which I consider one of the most exciting oncology-focused biotech companies. Despite the usual risks of an early-stage biotech, I find their p53 activator compound Kevetrin one of the most interesting things to follow.

However, when Cellceutix acquired PolyMedix assets from bankruptcy in September 2013, I was not sure what to make out of it. A biotech company developing cancer drugs is buying an antibiotic company's assets? I must admit that my impression was not positive at first. I prefer when an early-stage biotech company stays focused on the key compounds. After some time, I analyzed the acquisition in more depth and started developing a sneaking suspicion...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details